JCR Pharmaceuticals Co., Ltd. (4552) AI Stock Analysis

• Market Cap: ¥63.86B
• Dividend Yield: 3.77%
• Average Volume (3M): 1.88M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -22.86%
• EPS Growth: -188.19%
• Country: JP
• Employees: 934
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - General
• EPS (TTM): -33.80
• Shares Outstanding: 129,686,310
• 10 Day Avg. Volume: 862,920
• 30 Day Avg. Volume: 1,883,406
• PEG Ratio: 2.35
• Price to Book (P/B): 6.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 64.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥576.67
• Price Target Upside: 8.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 45 Neutral
• Price Target: ¥503.00 ▼(-5.09%Downside)

JCR Pharmaceuticals Co., Ltd. is facing significant financial difficulties, with negative profitability and cash flow issues being the most impactful factors. Technical indicators are weak, adding to bearish sentiment. Despite a high dividend yield, negative earnings make valuation challenging.

JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model

Company Description

JCR Pharmaceuticals Co., Ltd. is a Japan-based company engaged in the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes particularly in biopharmaceuticals, with a focus on enzyme replacement therapies and therapeutic proteins aimed at treating rare diseases. JCR is noted for its innovative drug delivery systems, as well as its commitment to improving patient outcomes through cutting-edge biotechnology solutions.

How the Company Makes Money

JCR Pharmaceuticals Co., Ltd. generates revenue primarily through the sale of its pharmaceutical products, particularly its proprietary biopharmaceuticals designed for the treatment of genetic and rare diseases. The company invests heavily in research and development to create innovative therapies, which are subsequently commercialized and distributed either independently or through strategic partnerships with other pharmaceutical companies. Revenue streams include product sales, licensing fees, and royalties from collaborations. Key partnerships with global pharmaceutical firms enhance market reach and product distribution, significantly contributing to JCR's earnings. Additionally, the company may receive government grants and incentives aimed at promoting research in rare diseases, further bolstering its financial performance.

JCR Pharmaceuticals Co., Ltd. Financial Statement Overview

Summary

The company faces significant financial challenges with negative margins and declining revenue. The balance sheet is stable but pressured by increasing debt levels. Cash flow issues are evident with negative operating and free cash flows, highlighting liquidity constraints.

Income Statement

The income statement reflects significant volatility. Gross profit margins were generally strong in past years but have suffered recently due to declining revenue and increased costs. The net profit margin has turned negative in the latest year, indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in the most recent year. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a stable equity base, but with a concerning rise in total debt, increasing the debt-to-equity ratio. Return on equity has turned negative due to recent net losses. However, the equity ratio remains healthy, indicating a strong asset base relative to liabilities. The financial structure suggests potential risks if the current trend of increasing debt continues.

Cash Flow

The cash flow statement highlights challenges with a negative free cash flow and operating cash flow in the latest period. The operating cash flow to net income ratio shows poor cash generation from operations, suggesting inefficiencies. The free cash flow has decreased significantly, raising concerns about the company's ability to fund operations and growth without external financing.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	35.03B	33.07B	42.87B	34.34B	51.08B	30.09B
Gross Profit	24.73B	21.55B	31.25B	25.46B	40.62B	22.27B
EBITDA	2.56B	-2.88B	10.53B	6.97B	21.88B	10.18B
Net Income	-228.00M	-4.76B	5.51B	3.77B	14.51B	6.89B
Balance Sheet
Total Assets	105.52B	104.86B	102.23B	94.94B	97.13B	73.78B
Cash, Cash Equivalents and Short-Term Investments	15.51B	13.20B	18.76B	13.28B	30.98B	26.26B
Total Debt	32.39B	38.10B	23.30B	22.80B	18.10B	18.10B
Total Liabilities	52.55B	57.42B	45.75B	42.52B	46.05B	35.23B
Stockholders Equity	52.58B	47.04B	56.18B	52.16B	50.88B	38.38B
Cash Flow
Free Cash Flow	0.00	-15.37B	7.22B	-14.06B	-2.04B	2.81B
Operating Cash Flow	0.00	-5.49B	9.31B	-5.50B	9.29B	10.34B
Investing Cash Flow	0.00	-9.87B	-2.69B	-15.00B	-3.25B	-3.29B
Financing Cash Flow	0.00	9.74B	-2.03B	1.95B	-2.18B	8.30B

JCR Pharmaceuticals Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 530.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4552, the sentiment is Negative. The current price of 530 is below the 20-day moving average (MA) of 535.95, above the 50-day MA of 511.50, and below the 200-day MA of 563.34, indicating a neutral trend. The MACD of -1.37 indicates Positive momentum. The RSI at 46.80 is Neutral, neither overbought nor oversold. The STOCH value of 53.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4552.

JCR Pharmaceuticals Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4886	76 Outperform	¥65.25B	13.63		2.03%	2.06%	-32.48%
4569	71 Outperform	¥78.43B	9.42		0.67%	8.83%	70.61%
4534	67 Neutral	€98.72B	18.09	4.35%	2.76%	5.31%	90.37%
3341	64 Neutral	¥90.87B	67.37	2.35%	0.80%	5.94%	-45.43%
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
4565	48 Neutral	$79.27B	―	-3.36%	―	87.83%	75.84%
4552	45 Neutral	¥63.86B	―		3.77%	-22.86%	-188.19%

JCR Pharmaceuticals Co., Ltd. Corporate Events

JCR Pharmaceuticals Announces Treasury Stock Disposition for Incentive Plan

JCR Pharmaceuticals Co., Ltd. announced a plan to dispose of 111,000 shares of its treasury stock as part of a restricted stock compensation plan aimed at incentivizing its directors and employees. This initiative is designed to align the interests of the company’s leadership with those of its shareholders, promoting sustained corporate value enhancement and ensuring continued commitment from key personnel.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Strengthens Ties with MEDIPAL HOLDINGS for Global Expansion

JCR Pharmaceuticals Co., Ltd. has announced its relationship with MEDIPAL HOLDINGS CORPORATION, which is its largest shareholder with a 23.86% voting rights ownership. The companies have a business alliance to enhance corporate value and growth, leveraging MEDIPAL’s distribution strengths and JCR’s pharmaceutical R&D capabilities. Recent agreements between the two include exclusive negotiation rights for the global commercialization of JCR’s new drug candidates targeting ultra-rare lysosomal storage diseases, and licensing agreements for treatments like JR-471 and JR-446. These collaborations are expected to bolster JCR’s industry positioning and operational capabilities.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Gain on Deferred Income Taxes

JCR Pharmaceuticals Co., Ltd. has announced a recognition of gain on deferred income taxes for the fiscal year ended March 31, 2025, resulting in a corporate tax adjustment profit of 1,771 million yen. This adjustment reflects the company’s performance trends and careful review of deferred tax assets’ recoverability, impacting the consolidated financial results positively and demonstrating JCR’s strategic financial management.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Leadership Transition for 2026

JCR Pharmaceuticals has announced a leadership transition effective April 1, 2026, marking a generational shift as the company celebrates its 50th anniversary. Toru Ashida will become Chairman and Hiroyuki Sonoda will assume the role of President, while current Chairman, President, and CEO Shin Ashida will transition to Founder and Director. This change aims to strengthen the management structure and enhance long-term corporate value.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Reports Significant Financial Losses for FY2024

JCR Pharmaceuticals reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with net sales dropping by 22.9% and a net loss of 4,759 million yen. The company is undergoing changes, including the exclusion of Mycenax Biotech Inc. from its subsidiaries and adjustments in accounting policies, as it aims to improve its financial standing and operational efficiency in the coming fiscal year.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Announces Consistent Dividend Distribution for 2025

JCR Pharmaceuticals Co., Ltd. announced the distribution of retained earnings as dividends, with a term-end dividend of 10.00 yen per share for the fiscal year ending March 31, 2025, matching the previous year’s dividend. This decision aligns with JCR’s policy of consistent profit distribution while maintaining reserves for new drug development and financial stability.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Nominates New Audit & Supervisory Board Members

JCR Pharmaceuticals Co., Ltd. announced the nomination of new candidates for its Audit & Supervisory Board, with appointments to be confirmed at the upcoming Ordinary General Meeting of Shareholders. This change reflects a strategic move to refresh its governance structure, potentially impacting its operational oversight and stakeholder confidence.